So Giancarlo, please tell us more and set the scene.

Yes.

So when I joined B1 as head of Europe, I joined this project because I know how much B1 trusts in the European potential to be a competitive hub, especially in cancer care.

Europe still detains a lot of innovation, a lot of competence, a lot of, I would say, education, science, and passion for treating cancer across the collaboration with the academics, scientists, key opinion leaders, doctors, but also caregivers in general.

So yes, it's true.

FPI is observing that there is a decline in investments.

In B1, we did exactly the opposite.

If we take all of that that we've discussed today, what would be the, perhaps let me phrase it differently, the central hope for that near-term future horizon and how it looks for patients?